오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

interpath services pty ltd - ct922 - microbiological culture media ivds - laboratory consumable swabs for collection and storage of microbiological culture media

미국 - 영어 - NLM (National Library of Medicine)

bioelements, inc. - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) -

미국 - 영어 - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - stellaria media (unii: 2h03479qvr) (stellaria media - unii:2h03479qvr) - rheumatism condition listed above or as directed by the physician

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

edwards group pty ltd - ct922 - microbiological culture media ivds - a culture media for the selection, growth, isolation and/or differentiation of tissue cells or microorganisms including bacteria, yeast, fungi and/or viruses from a clinical specimen.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 10.9 mg (equivalent: nebivolol, qty 10 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 5.45 mg (equivalent: nebivolol, qty 5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 2.725 mg (equivalent: nebivolol, qty 2.5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 1.363 mg (equivalent: nebivolol, qty 1.25 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 10.9 mg (equivalent: nebivolol, qty 10 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - nebivolol hydrochloride, quantity: 5.45 mg (equivalent: nebivolol, qty 5 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; croscarmellose sodium; hypromellose; polysorbate 80; microcrystalline cellulose; silicon dioxide; magnesium stearate - nebivolol is indicated: - to treat essential hypertension; - to treat stable chronic heart failure as an adjunct to standard therapies in patients 70 years or older.